ClinicalTrials.gg

Hoffmann-La Roche clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,744 studies whose lead sponsor is Hoffmann-La Roche or one of 15 companies grouped under it. 115 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 16 registry names, not the registry’s. See them and correct one ↓

Compare Hoffmann-La Roche with CSPC Pharmaceutical Group and Bristol-Myers Squibb →

Pipeline: 80 programs

Each counted once: 68 with a study Hoffmann-La Roche leads registered in the last two years, 12 more from Hoffmann-La Roche's own pipeline.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)
  • Named by Hoffmann-La Roche only (no registered study yet; not in the 80)

The 5 of 22 with the most live studies.

Program
inavolisibPhase 3 · 17 live · Breast Neoplasms · primary completion Dec 2026☆ Track
afimkibartPF06480605Phase 3 · Hoffmann-La Roche: Phase 3 · 14 live · Colitis, Ulcerative · primary completion Dec 2026☆ Track
giredestrantPhase 3 · Hoffmann-La Roche: Registration · 12 live · Breast Neoplasms · primary completion Jul 2027☆ Track
divarasibPhase 3 · Hoffmann-La Roche: Phase 3 · 9 live · Carcinoma, Non-Small-Cell Lung · primary completion Nov 2026☆ Track
glofitamabPhase 3 · 9 live · Lymphoma · primary completion Mar 2027☆ Track

17 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Hoffmann-La Roche’s own registered studies; “Hoffmann-La Roche says” is its pipeline, which lists phases by indication. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Licenses and deals

3 of Hoffmann-La Roche’s programs have a dated deal behind them: 1 brought in, 2 developed with a partner. Each from the companies’ own releases and filings, linked; the registry does not record them.

Brought in 1

Developed with a partner 2

What it is testing

The drugs Hoffmann-La Roche’s studies test, most open studies first — 335 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 335; every drug is on its own page, and each page lists its sponsors.

Coming up

79 of Hoffmann-La Roche’s studies under way reach primary completion within a year, 21 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 7N’26
  2. 9D
  3. 5J’27
  4. 2F
  5. 8M
  6. 5A
  7. 6M
  8. 13J
  9. 12J
  10. 3A
  11. 1S
  12. 4O
  13. 4N

The 12 nearest

Show 7 more

Add all 79 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting12

Show 7 more

All 2,744 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1154%Recruiting 104 · Not yet recruiting 10 · Enrolling by invitation 1
  • Under way, not recruiting1435%
  • Completed2,14378%
  • Stopped early32212%Terminated 267 · Withdrawn 53 · Suspended 2
  • Status unknown or other211%No longer available 7 · Approved for marketing 6 · Status unknown 6 · Available 2

Phase

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 22311
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 6926

By the year each study started; 410 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Hoffmann-La Roche.

  • Hoffmann-La Roche
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2,102 studies
  • Genentech, Inc.
    Acquired — became part of Hoffmann-La Roche, Sep 7, 1990 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    517 studies →
  • Chugai Pharmaceutical
    Acquired — became part of Hoffmann-La Roche, Oct 1, 2002 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    63 studies →
  • InterMune
    Acquired — became part of Hoffmann-La Roche, Sep 29, 2014 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    15 studies →
  • Spark Therapeutics, Inc.
    Acquired — became part of Hoffmann-La Roche, Dec 17, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    14 studies →
  • Carmot Therapeutics, Inc.
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies →
  • Poseida Therapeutics, Inc.
    Acquired — became part of Hoffmann-La Roche, Jan 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Telavant, Inc.
    Acquired — became part of Hoffmann-La Roche, Dec 14, 2023 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →
  • Chugai Pharma Taiwan
    Acquired — became part of Hoffmann-La Roche, Oct 1, 2002 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Chugai Pharma USA
    Acquired — became part of Hoffmann-La Roche, Oct 1, 2002 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Foundation Medicine
    Acquired — became part of Hoffmann-La Roche, Apr 7, 2015 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Roche Sequencing Solutions
    Division
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • Chugai Pharma France
    Acquired — became part of Hoffmann-La Roche, Oct 1, 2002 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • Roche Diagnostics GmbH
    Acquired — became part of Hoffmann-La Roche, Mar 5, 1998 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Chugai Pharma Europe Ltd.
    Acquired — became part of Hoffmann-La Roche, Oct 1, 2002 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Carmot Australia First Pty Ltd
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions Hoffmann-La Roche leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Show all 58 areas

Studies

Recruiting first, then most recently updated. Showing 50 of 2,744. Browse all 2,744 →